Literature Archives

Understanding mucus plug burden is increasingly relevant for IP-led bronchoscopic clearance interventions in severe asthma and COPD.

For clinicians, the study highlights that environmental and occupational risks contribute significantly to asthma, particularly among young adults where these risks account for 13.9% of the burden, and predicts that the global age-standardized prevalence rate will rise from approximately 4,132 per 100,000 in 2021 to 4,698 per 100,000 by 2050.

This trial will determine if starting with ultrasound elastography-guided biopsy is non-inferior to semi-rigid thoracoscopy using a non-inferiority margin of - 5% for diagnostic yield, potentially shifting practice toward a less invasive step-up approach and reducing the need for thoracoscopy.

Provides a potential future systemic therapeutic target for mesothelioma, which may influence the role of pleural biopsies and tissue acquisition in clinical trials.

Highlights the diagnostic utility of BALF in immunocompromised hosts and the limitations of blood-based surrogates.

Revisiting landmark IP trial data with Bayesian methods may alter the interpretation of procedural efficacy and clinical decision-making.

Endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy significantly outperforms standard transbronchial needle aspiration in diagnostic yield and overall accuracy for suspected mediastinal lymphoproliferative disorders.

For interventional pulmonologists, the nasal approach is a safe and feasible alternative that offers practical advantages, including reduced sedative requirements and fewer hypoxemia-related interruptions, while maintaining comparable diagnostic performance and complication rates to the oral route.

LTI-01 represents a significant pharmacological advancement in the management of complicated parapneumonic effusions and empyema, potentially reducing the need for surgical intervention.

Understanding sex-based differences in immunotherapy response is increasingly important for IP clinicians involved in the diagnostic and staging pathways of lung cancer.

IPs must stay updated on these systemic therapy shifts as they influence the timing and necessity of diagnostic and staging bronchoscopy in the multimodality care pathway.

EBUS-TBNA is a safe and highly effective diagnostic tool for tuberculous lymphadenitis, achieving an overall diagnostic sensitivity of 96.2% that remains consistent regardless of prior anti-tuberculosis treatment duration (P = 0.42).